Do you already have an account? Identify you
(Biotechnology stocks peak in weeks on August 13)
(Biotechnology reached a minimum of 52 weeks on August 13)
Novavax, Inc. (NASDAQ: NVAX) said it signed a contract with the UK for 60 million doses of NVX-CoV2373, its COVID-19 candidate vaccine.The company also agreed with the government on a phase 3 clinic.to compare the effectiveness of the vaccine in the British population.
Novavax said it would also expand its collaboration with FUJIFILM Diosynth Biotechnologies, which will manufacture the antigenic component of NVX-CoV2373 in Billingham, Stockton-on-Tees in the United Kingdom, in addition to its s in North Carolina and Texas in the United States.States.
The company has established partnerships for the manufacture and source of the vaccine, as it seeks to evolve production before the imaginable approval of emergency use.
In pre-trade, inventory was up 6.53% to $ 141.98.
Imara Inc (NASDAQ: IMRA) reported administering the first patient in its Phase 2b Ardent clinical trial on IMR-687 for patients with sickle cell disease.
“The first patient’s dosing in the Ardent clinical trial represents a step in the progression of CHECKS from IMR-687 to Phase 2b, a clinical trial that will check the highest doses and longer durations of IMR-687,” said Rahul Ballal, Imara’s executive director.
Inventory rose 3.91% to $21 after hours.
The shares of Israeli biopharmaceuticals Kamada Ltd.(NASDAQ: KMDA) were developing solidly. On Monday, the company announced the start of a phase 1/2 examination of its anti-SARS-CoV-2 plasma-derived immunoglobulin product as a possible remedy for COVID-19 in Israel.On Wednesday, the company released its second quarter effects, which appear below consensus and decrease revenue, leading to some inventory sales during the session.
Inventory rose 43% to $12.87 after hours.
It is very likely that the actions of Mesoblast Limited (NASDAQ: MESO), which stopped Thursday pending the announcement of an Adcom verdict, will increase after it said that the FDA’s Oncology Advisory Committee voted overwhelmingly in favor of knowledge that the effectiveness of remittance has to be supported. L in paediatric patients with acute graft disease as opposed to the steroid refractory host.
The experimental treatment, named after the Ryoncil industry, has a PDUFA action date of September 30, and the corporation said it plans to launch treatment in the United States in 2020.
TFF Pharmaceuticals stated that it has entered into an exclusive international license agreement with Union Therapeutics, which provides Union Therapeutics with the option to download an exclusive international license from the old generation of TFF for use in the niclosamide box, adding oral and inhalation.versions of niclosamide, potentially for COVID-19, as well as other niclosamide-based therapies.
Subject to Union’s agreement of his option, he has agreed to pay TFF milestone bills similar to development, regulation and sales of up to $210 million.Union will also pay one-digit royalties to TFF on product sales.
The corporations also agreed on co-paints to secure government assistance to finance the progression of niclosamide-based products for the COVID-19 remedy.
Inventory recovered 23.83% to $12.73 after hours.
Navidea Biopharmaceuticals Inc (NYSE: NAVB) reported second-quarter earnings of $271,000, up from $260,000 a year ago.Net loss consistent with a consistent percentage greater than 27 cents to 11 cents at the estimated consensus loss of 12 cents consistent with consistent percentage.
Inventory rose 18.30% to $3.75 after hours.
Molecular diagnostics company Myriad Genetics, Inc.(NASDAQ: MYGN) reported a 57% year-on-year decline in fourth-quarter earnings to $93.2 million.41 cents consistent with consistent percentage.
The corporate also announced the appointment of Paul Diaz as President and Chief Executive Officer, effective August 13, 2020.He will also on the board, he added.
Caladrius Biosciences Inc (NASDAQ: CLBS) went from a loss of 49 cents at the time of the 2019 quarter to a 50-cent profit consistent with a percentage consistent with 2020, thanks to a source of income tax benefit.
In out-of-hours operations, inventory added 6.05% to $2.28.
Co-Diagnostics Inc (NASDAQ: CODX) reported second-quarter earnings of $24.04 million, at $61,574 for last year.The company fell from an 8-cent loss consistent with a consistent percentage of 43 cents consistent with a consistent percentage, but fell below the consensus estimate of 59 cents consistent with the consistent percentage.
In out-of-hours operations, inventory fell 16.24% to $17.59.
Equillium Inc (NASDAQ: EQ) stated that it had valued its subscribed audience offering five million non-unusual shares to $7 consistent with the stock. Equillium said it expects to use gross supply revenue at approximately $3-5 million.The be offer is expected to close on or around August 18.
Inventory slid 15.53% to $7.45 out of hours.
OptiNose Inc (NASDAQ: OPTN) has announced the launch of a subscribed public offering of shares in its non-unusual actions.All non-unusual actions must be submitted through the company.
Optinose stated that it intends to use the net income from the be offer for operating capital and general corporate purposes, adding Xhance’s marketing, Xhance clinical progression for a follow-up indication for chronic sinusitis remedy and clinical progression of OPN-019 for COVID-19 repair.
In out-of-hours operations, inventory fell 13.04% to $5.90.
The German biotechnology company CureVac, which is preparing an mNR vaccine for the new coronavirus, has paid off its initial audience by providing 13.33 million inventories at $16 each, generating gross revenue of about $213.3 million.Inventories will begin trading on the Nasdaq under the CVAC inventory symbol.Recently, GlaxoSmithKline plc (NYSE: GSK) took a 10% stake in the company.
Thank you for subscribing! If you have any questions, please contact us at 1-877-440-ZING or email us at [email protected]